Microbial translocation in HIV infection

Causes, consequences and treatment opportunities

Netanya G. Sandler, Daniel C. Douek

Research output: Contribution to journalArticle

212 Citations (Scopus)

Abstract

Systemic immune activation is increased in HIV-infected individuals, even in the setting of virus suppression with antiretroviral therapy. Although numerous factors may contribute, microbial products have recently emerged as potential drivers of this immune activation. In this Review, we describe the intestinal damage that occurs in HIV infection, the evidence for translocation of microbial products into the systemic circulation and the pathways by which these products activate the immune system. We also discuss novel therapies that disrupt the translocation of microbial products and the downstream effects of microbial translocation.

Original languageEnglish (US)
Pages (from-to)655-666
Number of pages12
JournalNature Reviews Microbiology
Volume10
Issue number9
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

HIV Infections
Immune System
HIV
Viruses
Therapeutics

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Microbial translocation in HIV infection : Causes, consequences and treatment opportunities. / Sandler, Netanya G.; Douek, Daniel C.

In: Nature Reviews Microbiology, Vol. 10, No. 9, 09.2012, p. 655-666.

Research output: Contribution to journalArticle

Sandler, Netanya G. ; Douek, Daniel C. / Microbial translocation in HIV infection : Causes, consequences and treatment opportunities. In: Nature Reviews Microbiology. 2012 ; Vol. 10, No. 9. pp. 655-666.
@article{0e01cf97fd5241e5968d94d461fe9e7c,
title = "Microbial translocation in HIV infection: Causes, consequences and treatment opportunities",
abstract = "Systemic immune activation is increased in HIV-infected individuals, even in the setting of virus suppression with antiretroviral therapy. Although numerous factors may contribute, microbial products have recently emerged as potential drivers of this immune activation. In this Review, we describe the intestinal damage that occurs in HIV infection, the evidence for translocation of microbial products into the systemic circulation and the pathways by which these products activate the immune system. We also discuss novel therapies that disrupt the translocation of microbial products and the downstream effects of microbial translocation.",
author = "Sandler, {Netanya G.} and Douek, {Daniel C.}",
year = "2012",
month = "9",
doi = "10.1038/nrmicro2848",
language = "English (US)",
volume = "10",
pages = "655--666",
journal = "Nature Reviews Microbiology",
issn = "1740-1526",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Microbial translocation in HIV infection

T2 - Causes, consequences and treatment opportunities

AU - Sandler, Netanya G.

AU - Douek, Daniel C.

PY - 2012/9

Y1 - 2012/9

N2 - Systemic immune activation is increased in HIV-infected individuals, even in the setting of virus suppression with antiretroviral therapy. Although numerous factors may contribute, microbial products have recently emerged as potential drivers of this immune activation. In this Review, we describe the intestinal damage that occurs in HIV infection, the evidence for translocation of microbial products into the systemic circulation and the pathways by which these products activate the immune system. We also discuss novel therapies that disrupt the translocation of microbial products and the downstream effects of microbial translocation.

AB - Systemic immune activation is increased in HIV-infected individuals, even in the setting of virus suppression with antiretroviral therapy. Although numerous factors may contribute, microbial products have recently emerged as potential drivers of this immune activation. In this Review, we describe the intestinal damage that occurs in HIV infection, the evidence for translocation of microbial products into the systemic circulation and the pathways by which these products activate the immune system. We also discuss novel therapies that disrupt the translocation of microbial products and the downstream effects of microbial translocation.

UR - http://www.scopus.com/inward/record.url?scp=84865163472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865163472&partnerID=8YFLogxK

U2 - 10.1038/nrmicro2848

DO - 10.1038/nrmicro2848

M3 - Article

VL - 10

SP - 655

EP - 666

JO - Nature Reviews Microbiology

JF - Nature Reviews Microbiology

SN - 1740-1526

IS - 9

ER -